Li Jin
Li Jin has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Yingli He
Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
3 shared publications ChunHua Hu
Institution of Hepatology, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China
2 shared publicationsJinFeng Liu
Institution of Hepatology, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China
2 shared publicationsTianYan Chen
Institution of Hepatology, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China
2 shared publicationsYi Chen
Institution of Hepatology, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China
2 shared publicationsYingRen Zhao
Institution of Hepatology, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China
2 shared publications
Latest Publications
- Open Access
- 21 January 2026
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 75 (1)
Antibiotic exposure exacerbates acute-on-chronic liver failure via gut microbiota imbalance and secondary liver lesion
Introduction. The correlation between antibiotic exposure and adverse outcomes in patients with acute-on-chronic liver failure (ACLF) remains controversial, and the underlying mechanism is unclear. Hypothesis/Gap Statement. This study hypothesizes that antibiotic exposure in ACLF patients alters gut microbiota, which affects the outcome of ACLF. Aim. To explore the effect of antibiotic exposure on gut microbiota that affects the outcome of ACLF. Methodology. A retrospective matched study of ACLF patients and the ACLF rat model was used to assess adverse outcomes associated with antibiotic exposure. The gut microbiota of the ACLF patients and the ACLF rat model were sequenced using the Illumina MiSeq platform. Results. Twenty-three ACLF patients who were exposed to antibiotics and 46 matched controls who were not exposed to antibiotics were enrolled. The survival rates at 4, 12 and 24 weeks were significantly lower in the exposure group than in the non-exposure group. In the ACLF rat model, hepatitis in the antibiotic-exposure group became more severe, and the alanine transaminase levels were higher than those of the non-exposure group. The gut microbiota diversity was decreased in the ACLF patients with antibiotic exposure, and the proportions of Enterococcaceae and Peptostreptococcaceae were increased, while those of Lachnospiraceae , Bifidobacteriaceae and Bacteroidaceae were decreased. In the rat model, antibiotic exposure induced Gram-positive and Gram-negative bacterial eradication, and Klebsiella became the dominant micro-organism. Conclusion. Antibiotic exposure aggravated hepatitis and had no survival benefit for ACLF. The underlying mechanism may be related to dysbiosis in the gut microbiota.
- 21 January 2026
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 75 (1)
Open AccessAntibiotic exposure exacerbates acute-on-chronic liver failure via gut microbiota imbalance and secondary liver lesion
Introduction. The correlation between antibiotic exposure and adverse outcomes in patients with acute-on-chronic liver failure (ACLF) remains controversial, and the underlying mechanism is unclear. Hypothesis/Gap Statement. This study hypothesizes that antibiotic exposure in ACLF patients alters gut microbiota, which affects the outcome of ACLF. Aim. To explore the effect of antibiotic exposure on gut microbiota that affects the outcome of ACLF. Methodology. A retrospective matched study of ACLF patients and the ACLF rat model was used to assess adverse outcomes associated with antibiotic exposure. The gut microbiota of the ACLF patients and the ACLF rat model were sequenced using the Illumina MiSeq platform. Results. Twenty-three ACLF patients who were exposed to antibiotics and 46 matched controls who were not exposed to antibiotics were enrolled. The survival rates at 4, 12 and 24 weeks were significantly lower in the exposure group than in the non-exposure group. In the ACLF rat model, hepatitis in the antibiotic-exposure group became more severe, and the alanine transaminase levels were higher than those of the non-exposure group. The gut microbiota diversity was decreased in the ACLF patients with antibiotic exposure, and the proportions of Enterococcaceae and Peptostreptococcaceae were increased, while those of Lachnospiraceae , Bifidobacteriaceae and Bacteroidaceae were decreased. In the rat model, antibiotic exposure induced Gram-positive and Gram-negative bacterial eradication, and Klebsiella became the dominant micro-organism. Conclusion. Antibiotic exposure aggravated hepatitis and had no survival benefit for ACLF. The underlying mechanism may be related to dysbiosis in the gut microbiota.
- Open Access
- 27 October 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2568651
Leukocyte telomere length mediates the association between SIRI and CKD: insights from NHANES 1999–2002
Chronic kidney disease (CKD) is closely linked to systemic inflammation and accelerated cellular aging. However, the role of the systemic inflammation response index (SIRI) and leukocyte telomere length (LTL), a biomarker of cellular aging, in the development and progression of CKD remain incompletely elucidated. We analyzed cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) (1999-2002), which included 3805 individuals. Participants were divided into subgroups: (1) CKD versus non-CKD and (2) SIRI quartiles (Q1-Q4). SIRI was calculated as (monocytes × neutrophils)/lymphocytes. CKD was defined by urinary albumin to creatinine ratio (UACR) ≥30 mg/g or estimated glomerular filtration rate (eGFR) 2. LTL was quantified by quantitative polymerase chain reaction (qPCR). Weighted logistic regression models used to assess the associations of SIRI, LTL, and CKD, adjusting for demographics, socioeconomic factors, lifestyle, and comorbidities. Mediation analysis was performed to quantify the indirect effect of SIRI on CKD via LTL shortening. Participants with CKD exhibited significantly higher SIRI values (p < 0.001) and shorter LTL (p < 0.001) compared those without CKD. In fully adjusted models, higher SIRI quartiles showed a dose-response relationship with CKD risk: Q3 (OR = 1.442, p = 0.046) and Q4 (OR = 2.165, p < 0.001). Conversely, longer LTL was inversely associated with CKD risk across quartiles: Q2 (OR = 0.681, p = 0.047), Q3 (OR = 0.567, p = 0.015), and Q4 (OR = 0.445, p = 0.004). Furthermore, higher SIRI quartiles showed significant inverse associations with LTL compared to Q1: Q3 (OR = 0.955, p = 0.040) and Q4 (OR = 0.944, p = 0.007). Mediation analysis showed that LTL mediated 7.8% (95% CI: 4.12%, 15.63%) of the total effect of SIRI on CKD (indirect effect: OR = 1.002, p < 0.001), while the direct effect remained statistically significant (OR = 1.026, p < 0.001). Sensitivity analyses verified the robustness of the results. Systemic inflammation, as quantified by the SIRI, has a significant impact on CKD risk through its contribution to LTL attrition. This process highlights the complex interplay between systemic inflammation and biological aging in the pathophysiology of CKD.
- 27 October 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2568651
Open AccessLeukocyte telomere length mediates the association between SIRI and CKD: insights from NHANES 1999–2002
Chronic kidney disease (CKD) is closely linked to systemic inflammation and accelerated cellular aging. However, the role of the systemic inflammation response index (SIRI) and leukocyte telomere length (LTL), a biomarker of cellular aging, in the development and progression of CKD remain incompletely elucidated. We analyzed cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) (1999-2002), which included 3805 individuals. Participants were divided into subgroups: (1) CKD versus non-CKD and (2) SIRI quartiles (Q1-Q4). SIRI was calculated as (monocytes × neutrophils)/lymphocytes. CKD was defined by urinary albumin to creatinine ratio (UACR) ≥30 mg/g or estimated glomerular filtration rate (eGFR) 2. LTL was quantified by quantitative polymerase chain reaction (qPCR). Weighted logistic regression models used to assess the associations of SIRI, LTL, and CKD, adjusting for demographics, socioeconomic factors, lifestyle, and comorbidities. Mediation analysis was performed to quantify the indirect effect of SIRI on CKD via LTL shortening. Participants with CKD exhibited significantly higher SIRI values (p < 0.001) and shorter LTL (p < 0.001) compared those without CKD. In fully adjusted models, higher SIRI quartiles showed a dose-response relationship with CKD risk: Q3 (OR = 1.442, p = 0.046) and Q4 (OR = 2.165, p < 0.001). Conversely, longer LTL was inversely associated with CKD risk across quartiles: Q2 (OR = 0.681, p = 0.047), Q3 (OR = 0.567, p = 0.015), and Q4 (OR = 0.445, p = 0.004). Furthermore, higher SIRI quartiles showed significant inverse associations with LTL compared to Q1: Q3 (OR = 0.955, p = 0.040) and Q4 (OR = 0.944, p = 0.007). Mediation analysis showed that LTL mediated 7.8% (95% CI: 4.12%, 15.63%) of the total effect of SIRI on CKD (indirect effect: OR = 1.002, p < 0.001), while the direct effect remained statistically significant (OR = 1.026, p < 0.001). Sensitivity analyses verified the robustness of the results. Systemic inflammation, as quantified by the SIRI, has a significant impact on CKD risk through its contribution to LTL attrition. This process highlights the complex interplay between systemic inflammation and biological aging in the pathophysiology of CKD.
- 5 September 2023
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (12) , 1060-1066
The association of serum anti-PLA2R antibody and glomerular PLA2R antigen staining with clinical manifestations and outcomes in membranous nephropathy
Background Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) was manifested as seropositive for PLA2R antibodies (SAb) and/or glomerular PLA2R antigens’ (GAg) deposits. According to the test of SAb and GAg, PLA2R-associated MN can be divided into SAb + /GAg−, SAb−/GAg + , and SAb + /GAg + groups. The clinical characteristics and outcomes of the three groups need to be further evaluated. Methods 184 PLA2R-associated MN patients were enrolled. SAb was measured by enzyme-linked immunosorbent assay with a cut-off value of 14 RU/mL. GAg was detected by immunofluorescence using a paraffin section of renal biopsy samples. Clinical characteristics and the decline of eGFR were compared among the 3 groups. Results There were 33 SAb + /GAg−, 46 SAb−/GAg +, and 105 SAb + /GAg + PLA2R-associated MN patients reviewed. Clinical characteristics, such as the level of proteinuria, serum albumin, as well as eGFR, were comparable between the SAb + /GAg− and SAb + /GAg + patients. While SAb−/GAg + patients exhibited mild clinical manifestations as evidenced by higher serum albumin (P < 0.001) and lower proteinuria (p = 0.049) compared with SAb + /GAg + patients. After 21.96 ± 7.39 month follow-up, the eGFR decrease was no difference between the SAb + /GAg− and SAb + /GAg + patients. SAb−/GAg + patients had a lower rate of the > 20% eGFR decline as well as a 50% eGFR decline compared with the SAb + /GAg + patients (10.87% vs 30.48%, p = 0.013; 0.00% vs 4.76%, p = 0.324). Conclusions Our study showed that the clinical manifestations of SAb + /Gag− patients were the same as those of double-positive patients, while SAb−/GAg + patients exhibited mild clinical manifestations and slower eGFR decline compared to the double-positive patients.
- 5 September 2023
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (12) , 1060-1066
The association of serum anti-PLA2R antibody and glomerular PLA2R antigen staining with clinical manifestations and outcomes in membranous nephropathy
Background Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) was manifested as seropositive for PLA2R antibodies (SAb) and/or glomerular PLA2R antigens’ (GAg) deposits. According to the test of SAb and GAg, PLA2R-associated MN can be divided into SAb + /GAg−, SAb−/GAg + , and SAb + /GAg + groups. The clinical characteristics and outcomes of the three groups need to be further evaluated. Methods 184 PLA2R-associated MN patients were enrolled. SAb was measured by enzyme-linked immunosorbent assay with a cut-off value of 14 RU/mL. GAg was detected by immunofluorescence using a paraffin section of renal biopsy samples. Clinical characteristics and the decline of eGFR were compared among the 3 groups. Results There were 33 SAb + /GAg−, 46 SAb−/GAg +, and 105 SAb + /GAg + PLA2R-associated MN patients reviewed. Clinical characteristics, such as the level of proteinuria, serum albumin, as well as eGFR, were comparable between the SAb + /GAg− and SAb + /GAg + patients. While SAb−/GAg + patients exhibited mild clinical manifestations as evidenced by higher serum albumin (P < 0.001) and lower proteinuria (p = 0.049) compared with SAb + /GAg + patients. After 21.96 ± 7.39 month follow-up, the eGFR decrease was no difference between the SAb + /GAg− and SAb + /GAg + patients. SAb−/GAg + patients had a lower rate of the > 20% eGFR decline as well as a 50% eGFR decline compared with the SAb + /GAg + patients (10.87% vs 30.48%, p = 0.013; 0.00% vs 4.76%, p = 0.324). Conclusions Our study showed that the clinical manifestations of SAb + /Gag− patients were the same as those of double-positive patients, while SAb−/GAg + patients exhibited mild clinical manifestations and slower eGFR decline compared to the double-positive patients.
- 1 March 2022
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 322 (3) , G360-G367
MAPK p38/Ulk1 pathway inhibits autophagy and induces IL-1β expression in hepatic stellate cells
LPS inhibits autophagy in a concentration- and dose-dependent manner in HSC-T6 cells. MAPK p38 induces phosphorylation of Ulk1, which disrupts the Ulk1-Atg13 complex and is therefore required for the inhibition of autophagy by LPS. LPS induces IL-1β expression via the MAPK p38/Ulk1 pathway in HSCs.
- 1 March 2022
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 322 (3) , G360-G367
MAPK p38/Ulk1 pathway inhibits autophagy and induces IL-1β expression in hepatic stellate cells
LPS inhibits autophagy in a concentration- and dose-dependent manner in HSC-T6 cells. MAPK p38 induces phosphorylation of Ulk1, which disrupts the Ulk1-Atg13 complex and is therefore required for the inhibition of autophagy by LPS. LPS induces IL-1β expression via the MAPK p38/Ulk1 pathway in HSCs.
- Open Access
- 8 October 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Auditory Neuropathy as the Initial Phenotype for Patients With ATP1A3 c.2452 G > A: Genotype–Phenotype Study and CI Management
Objective: The objective of this study is to analyze the genotype–phenotype correlation of patients with auditory neuropathy (AN), which is a clinical condition featuring normal cochlear responses and abnormal neural responses, and ATP1A3 c.2452 G > A (p.E818K), which has been generally recognized as a genetic cause of cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS) syndrome.Methods: Four patients diagnosed as AN by clinical evaluation and otoacoustic emission and auditory brainstem responses were recruited and analyzed by next-generation sequencing to identify candidate disease-causing variants. Sanger sequencing was performed on the patients and their parents to verify the results, and short tandem repeat-based testing was conducted to confirm the biological relationship between the parents and the patients. Furthermore, cochlear implantation (CI) was performed in one AN patient to reconstruct hearing.Results: Four subjects with AN were identified to share a de novo variant, p.E818K in the ATP1A3 gene. Except for the AN phenotype, patients 1 and 2 exhibited varying degrees of neurological symptoms, implying that they can be diagnosed as CAPOS syndrome. During the 15 years follow-up of patient 1, we observed delayed neurological events and progressive bilateral sensorineural hearing loss in pure tone threshold (pure tone audiometry, PTA). Patient 2 underwent CI on his left ear, and the result was poor. The other two patients (patient 3 and patient 4, who were 8 and 6 years old, respectively) denied any neurological symptoms.Conclusion:ATP1A3 p.E818K has rarely been documented in the Chinese AN population. Our study confirms that p.E818K in the ATP1A3 gene is a multiethnic cause of AN in Chinese individuals. Our study further demonstrates the significance of genetic testing for this specific mutation for identifying the special subtype of AN with somewhat favorable CI outcome and offers a more accurate genetic counseling about the specific de novo mutation.
- 8 October 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Open AccessAuditory Neuropathy as the Initial Phenotype for Patients With ATP1A3 c.2452 G > A: Genotype–Phenotype Study and CI Management
Objective: The objective of this study is to analyze the genotype–phenotype correlation of patients with auditory neuropathy (AN), which is a clinical condition featuring normal cochlear responses and abnormal neural responses, and ATP1A3 c.2452 G > A (p.E818K), which has been generally recognized as a genetic cause of cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS) syndrome.Methods: Four patients diagnosed as AN by clinical evaluation and otoacoustic emission and auditory brainstem responses were recruited and analyzed by next-generation sequencing to identify candidate disease-causing variants. Sanger sequencing was performed on the patients and their parents to verify the results, and short tandem repeat-based testing was conducted to confirm the biological relationship between the parents and the patients. Furthermore, cochlear implantation (CI) was performed in one AN patient to reconstruct hearing.Results: Four subjects with AN were identified to share a de novo variant, p.E818K in the ATP1A3 gene. Except for the AN phenotype, patients 1 and 2 exhibited varying degrees of neurological symptoms, implying that they can be diagnosed as CAPOS syndrome. During the 15 years follow-up of patient 1, we observed delayed neurological events and progressive bilateral sensorineural hearing loss in pure tone threshold (pure tone audiometry, PTA). Patient 2 underwent CI on his left ear, and the result was poor. The other two patients (patient 3 and patient 4, who were 8 and 6 years old, respectively) denied any neurological symptoms.Conclusion:ATP1A3 p.E818K has rarely been documented in the Chinese AN population. Our study confirms that p.E818K in the ATP1A3 gene is a multiethnic cause of AN in Chinese individuals. Our study further demonstrates the significance of genetic testing for this specific mutation for identifying the special subtype of AN with somewhat favorable CI outcome and offers a more accurate genetic counseling about the specific de novo mutation.
- Open Access
- 18 January 2019
- Published by Wiley in Cancer Science
- Vol. 110 (3) , 1054-1063
Nitric oxide inhibits autophagy and promotes apoptosis in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the second most common cause of cancer‐related mortality worldwide. The expression of nitric oxide synthase (NOS) and the inhibition of autophagy have been linked to cancer cell death. However, the involvement of serum nitric oxide (NO), the expression of NOS and autophagy have not been investigated in HCC. In the present study, we first established that the NO level was significantly higher in hepatitis B virus‐related HCC than in the liver cirrhosis control (53.60 ± 19.74 vs 8.09 ± 4.17 μmol/L, t = 15.13, P < 0.0001). Using immunohistochemistry, we found that the source of NO was at least partially attributed to the expression of inducible NOS and endothelial NOS but not neuronal NOS in the liver tissue. Furthermore, in human liver cancer cells, NO‐induced apoptosis and inhibited autophagy. Pharmacological inhibition of autophagy also induced apoptosis, whereas the induction of autophagy could ameliorate NO‐induced apoptosis. We also found that NO regulates the switch between apoptosis and autophagy by disrupting the Beclin 1/Vps34 association and by increasing the Bcl‐2/Beclin 1 interaction. Overall, the present findings suggest that increased NOS/NO promotes apoptosis through the inhibition of autophagy in liver cancer cells, which may provide a novel strategy for the treatment of HCC.
- 18 January 2019
- Published by Wiley in Cancer Science
- Vol. 110 (3) , 1054-1063
Open AccessNitric oxide inhibits autophagy and promotes apoptosis in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the second most common cause of cancer‐related mortality worldwide. The expression of nitric oxide synthase (NOS) and the inhibition of autophagy have been linked to cancer cell death. However, the involvement of serum nitric oxide (NO), the expression of NOS and autophagy have not been investigated in HCC. In the present study, we first established that the NO level was significantly higher in hepatitis B virus‐related HCC than in the liver cirrhosis control (53.60 ± 19.74 vs 8.09 ± 4.17 μmol/L, t = 15.13, P < 0.0001). Using immunohistochemistry, we found that the source of NO was at least partially attributed to the expression of inducible NOS and endothelial NOS but not neuronal NOS in the liver tissue. Furthermore, in human liver cancer cells, NO‐induced apoptosis and inhibited autophagy. Pharmacological inhibition of autophagy also induced apoptosis, whereas the induction of autophagy could ameliorate NO‐induced apoptosis. We also found that NO regulates the switch between apoptosis and autophagy by disrupting the Beclin 1/Vps34 association and by increasing the Bcl‐2/Beclin 1 interaction. Overall, the present findings suggest that increased NOS/NO promotes apoptosis through the inhibition of autophagy in liver cancer cells, which may provide a novel strategy for the treatment of HCC.